New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 8, 2014
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
08:31 EDTBDXBecton Dickinson and CareFusion sets date for special meeting in proposed merger
Becton, Dickinson (BDX) and CareFusion (CFN) announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval is a condition to the merger. In addition to CareFusion stockholder approval, the proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation. CareFusion has fixed the close of business on December 18, 2014 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, the special meeting.
08:21 EDTTEVAMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
07:53 EDTDHRDanaher price target raised to $100 from $89 at Jefferies
Jefferies raised its price target for Danaher shares to $100 ahead of the company's investor day and keeps a Buy rating on the name. It expects an initial 2015 organic growth outlook of 3% and earnings guidance of $3.95 and ex-amortization $4.40. Jefferies keeps a Buy rating on the stock.
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
December 5, 2014
15:49 EDTBDXBecton Dickinson, Aethon announce collaboration
Subscribe for More Information
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Subscribe for More Information
08:07 EDTOMIOwens & Minor sees 10% growth in adjusted EPS in FY15, consensus $1.93
Subscribe for More Information
07:54 EDTTEVALannett names Michael Bogda as president, effective December 1
Subscribe for More Information
07:37 EDTGILDGilead price target raised to $121 from $110 at JPMorgan
JPMorgan raised its price target for Gilead shares to $121 saying the company's potential cash flow generation is "immense" and provides "significant strategic flexibility." The firm estimates Gilead can generate more than $30B in cash in the next two years and $80B-plus over the next five years. It keeps an Overweight rating on the stock.
05:55 EDTBDXCDC data postiive for flu testing companies, says Piper Jaffray
Subscribe for More Information
December 4, 2014
10:32 EDTTEVATeva receives positive outcomes in Europe for three-times-a-week COPAXONE
Teva Pharmaceutical Industries announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis RMS. The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency, and all Concerned Member States in Europe who were involved in the procedure. Granting of national authorizations will happen in the near future. The three-times-a-week COPAXONE 40 mg/ml formulation will allow for an improved, less-frequent, subcutaneous dosing regimen for adults with RMS. The new formulation reduces the total number of injections by almost 60%, while maintaining the known benefits of once daily COPAXONE 20 mg/ml. “We welcome the opportunity to make COPAXONE 40 mg/ml available to patients with RMS in Europe,” said Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva. “Three-times-a-week COPAXONE 40 mg/ml will be available in Europe as early as the first quarter of 2015 with expected launches in Germany, Netherlands and Denmark. Launches in other EU countries are expected throughout 2015.”
09:01 EDTGILDVA negotiated $594 per dose price for Gilead HCV treatment
A Veterans Health Administration official told a Senate committee yesterday that Veterans' Affairs has "moved rapidly to deploy new, more effective, less toxic HCV treatments and has been able to negotiate significant discounts for these newer therapies." The agency negotiated a price of $594 per dose for Gilead's (GILD) Hepatitis C virus drug Sofosbuvir, below the commercial price of $1,000 per dose, VHA Chief Consultant for Pharmacy Benefits Management Michael Valentino told the Senate's Committee on Veterans' Affairs. The agency also received a $413 per dose price for Johnson & Johnson's (JNJ) Simeprevir, below the commerical price of $790. The VA has approximately 174,000 veterans in care with HCV, making it the largest single HCV provider in the U.S., Valentino pointed out. He added, "Like the rest of the country, VA has treated only a portion of Veterans for HCV because treatment and cures have been difficult to achieve due to low efficacy and high toxicity of standard drug therapies." Reference Link
05:30 EDTTEVACTI BioPharma receives $15M payment from Teva for TRISENOX
Subscribe for More Information
December 3, 2014
17:36 EDTDHRNetScout files preliminary registration statement for Danaher purchase
Subscribe for More Information
16:00 EDTGILDOptions Update; December 3, 2014
iPath S&P 500 VIX Short-Term Futures down 45c to 26.52. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX C GILD RIG ABX according to Track Data.
10:00 EDTPKIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aldeyra (ALDX) initiated with a Buy at Ascendiant... Baker Hughes (BHI) initiated with a Perform at Oppenheimer... Belmond Ltd (BEL) initiated with an Outperform at JMP Securities... Bruker (BRKR) initiated with a Buy at BTIG... Cepheid (CPHD) initiated with a Neutral at BTIG... ClubCorp (MYCC) initiated with a Buy at KeyBanc... GenMark (GNMK) initiated with a Buy at BTIG... Halliburton (HAL) initiated with an Outperform at Oppenheimer... MetLife (MET) initiated with a Neutral at Atlantic Equities... PerkinElmer (PKI) initiated with a Neutral at BTIG... Principal Financial (PFG) initiated with an Overweight at Atlantic Equities... Prudential (PRU) initiated with an Overweight at Atlantic Equities... SanDisk (SNDK) initiated with a Buy, $125 target at Citigroup... Schlumberger (SLB) initiated with an Outperform at Oppenheimer... Talmer Bancorp (TLMR) initiated with an Outperform at Fig Partners... W.P. Carey (WPC) initiated with a Neutral at Citigroup... WNS Holdings (WNS) initiated with a Buy at Maxim... Weatherford (WFT) initiated with an Outperform at Oppenheimer.
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:09 EDTPKIPerkinElmer initiated with a Neutral at BTIG
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use